Clinical trial · Interventional
Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
Randomized Clinical Trial:Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Research purpose To elucidate the effect mechanism and clinical effective of Modified Banxia Xiexin Decoction in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of Modified Banxia Xiexin Decoction's treatment on gastric cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer (Diagnosis) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| combination chemotherapy with Placebo granules | Drug | — | UNRESOLVED |
| Modified Banxia Xiexin Decoction | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- combination chemotherapy with Modified Banxia Xiexin Decoction
- description
- 146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases. The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction
- interventionNames
- Drug: Modified Banxia Xiexin Decoction
- type
- PLACEBO_COMPARATOR
- label
- combination chemotherapy with Placebo granules
- description
- The control group received combination chemotherapy with Placebo granules.
- interventionNames
- Drug: combination chemotherapy with Placebo granules
Primary outcomes (1)
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with stage IV gastric cancer with a clear cytological or pathological diagnosis. 2. The patient is willing to receive palliative chemotherapy (more than 6 months between the first treatment or the last chemotherapy). 3. At least one measurable lesion revealed by imaging (PET-CT, CT, MRI, bone scan, x-ray). 4. Expected survival of ≥ 6 months. 5. It is consistent with the diagnosis of spleen qi deficiency and cold-heat mismatch in TCM. 6. Age 18 to 75 years with a physical condition score of ECOG (0-1). 7. The blood count is normal, heart, liver and kidney functions are not abnormal, and the electrocardiogram is basically normal. 8. Patients have good compliance, are able to understand the study and sign an informed consent form. Exclusion Criteria: 1. Those with a history of severe cardiovascular, urinary, hematological and digestive system diseases. 2. Pregnant or breastfeeding women with uncontrollable mental disorders. 3. With gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia. 4. Complications of serious infectious diseases such as active tuberculosis. 5. Those with contraindications to chemotherapy or frequent vomiting. 6. Poor compliance. 7. Patients who have used other trial drugs or in other clinical trials in the past month.
References
Publications (0)
Data not yet available